Fig. 1From: Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cellsStudy outline of kinase inhibitor screening. Three BRAF mutated melanoma cell lines, A375, IGR37 and 501Mel (each one in its parental (P), Vemurafenib (XP)- and Dabrafenib (GP)-resistant form) were treated with 2 concentrations (1 and 10 μM) of 274 different kinase inhibitors. 40 promising candidates were further characterized in dose-response assays, which led to the identification of 14 compounds that were used in combination treatments where synergism was assessed. Short- and long-term effects of combinations with 8 successful drugs were analyzed: Danusertib (Aurora kinase, FGFR, Bcr-Abl, c-RET, Src inhibitor), MK-1775 (Wee1 inhibitor), AZD7762 (Chk inhibitor), AZD8330 (MEK inhibitor), CHIR-124 (Chk inhibitor), Volasertib (Plk inhibitor), PIK-75 (PI3K, DNA-PK inhibitor), TAE226 (FAK inhibitor). BRAFi: BRAF inhibitor, Vemurafenib or DabrafenibBack to article page